NYSE Shariah screener · October 2026

Is Abbott Laboratories (ABT) Halal?

PASS

Abbott Laboratories · NYSE: ABT · Healthcare

The short answer

Yes — Abbott Laboratories (ABT) passes this Shariah stock screen at all three gates. Abbott, headquartered in Abbott Park, Illinois, sells medical devices (~48% of FY2025 sales — FreeStyle Libre glucose monitors, cardiac devices), diagnostics (~20%), nutrition (~19% — Similac, Pedialyte, Ensure), and branded generic pharmaceuticals (~12.5%) — none involve alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance. The financial ratios pass comfortably: total debt of $32,608M is about 19.49% of its ~$167.31B market cap ($96.69/share, October 1, 2026), below the ~33% ceiling, and interest income of $308M is about 0.69% of FY2025 revenue ($44,328M), below the 5% ceiling. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

Abbott Laboratories (NYSE: ABT), headquartered in Abbott Park, Illinois (CEO Robert B. Ford; ~114,000 employees), reports four segments per its FY2025 10-K: Medical Devices ($21,387M of $44,328M sales, ~48% — FreeStyle Libre CGMs/Diabetes Care $7,998M, rhythm management, electrophysiology, vascular, structural heart, neuromodulation), Diagnostic Products ($8,937M, ~20% — core laboratory, molecular, point-of-care, rapid diagnostics), Nutritional Products ($8,451M, ~19% — Similac infant formula, Pedialyte, PediaSure, Ensure), and Established Pharmaceutical Products ($5,536M, ~12.5% — branded generics in key emerging markets). Abbott spun off its research-based pharmaceuticals business as AbbVie in 2013 (separate company). Business-screen implication (factual): every segment sells healthcare products — none involve alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per Abbott's Q2 2026 Form 10-Q (period ended June 30, 2026; SEC CIK 1800), total debt was $32,608M — current portion of long-term debt $3,005M + long-term debt $29,603M. Against a market cap of about $167.31B (1,730,383,296 shares outstanding × $96.69, October 1, 2026, per Finnhub), debt ÷ market cap is about 19.49% — below the ~33% ceiling. Cash and cash equivalents of $5,104M is about 3.05% of market cap. Debt rose sharply in H1 2026 (from $12,929M at Dec 31, 2025), alongside jumps in goodwill and intangible assets. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

Abbott's FY2025 Form 10-K (SEC EDGAR accession abt-20251231; CIK 1800) reports interest (income) of $308M against FY2025 net sales of $44,328M — about 0.69% of revenue, below the 5% non-compliant income ceiling. Line used: the Consolidated Statement of Earnings 'Interest (income)' line. Gate 3 passes. Facts only.

Key figures used

Business: four segments — Medical Devices ($21,387M, ~48% of FY2025 sales; FreeStyle Libre CGMs $7,998M, rhythm management, electrophysiology, vascular, structural heart, neuromodulation), Diagnostic Products ($8,937M, ~20%), Nutritional Products ($8,451M, ~19%; Similac, Pedialyte, PediaSure, Ensure), Established Pharmaceutical Products ($5,536M, ~12.5%; branded generics, key emerging markets)
No haram segments: all revenue from healthcare products — no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance; AbbVie spun off in 2013 and trades separately
Debt: $32,608M (current portion of LT debt $3,005M + LT debt $29,603M, Q2 2026 10-Q) — debt ÷ market cap ≈ 19.49% of ~$167.31B (1,730,383,296 shares × $96.69, Oct 1, 2026), under the ~33% ceiling
Debt rose sharply in H1 2026: $12,929M (Dec 31, 2025) → $32,608M, alongside jumps in goodwill ($35,244M) and intangible assets ($17,211M)
Cash: $5,104M cash and cash equivalents ≈ 3.05% of market cap
Interest income: $308M ('Interest (income)' line, FY2025 10-K) vs revenue $44,328M — ≈0.69% of revenue, under the 5% ceiling
Zoya: ABT page exists but rating inconclusive (contradictory auto-generated page text; cites $230M interest income vs 10-K's $308M); Musaffa: no ABT page; ShariaPortfolio: no ABT entry

Frequently asked questions

What does Abbott do?

Abbott Laboratories (NYSE: ABT), headquartered in Abbott Park, Illinois, is a global healthcare company founded in 1888 (CEO Robert B. Ford; ~114,000 employees). It reports four segments: Medical Devices (~48% of FY2025 sales — FreeStyle Libre continuous glucose monitors, cardiac rhythm management, electrophysiology, vascular, structural heart, neuromodulation), Diagnostic Products (~20% — core laboratory immunoassays, molecular, point-of-care and rapid diagnostics), Nutritional Products (~19% — Similac infant formula, Pedialyte, PediaSure, Ensure adult nutrition), and Established Pharmaceutical Products (~12.5% — branded generics sold primarily in key emerging markets). Abbott spun off its research-based pharmaceuticals business as AbbVie in 2013 and trades separately from it.

Why does Abbott pass this Shariah stock screen?

Abbott passes this Shariah stock screen at all three gates. Gate 1 (business activity): all four segments — medical devices, diagnostics, nutrition, and established pharmaceuticals — sell healthcare products; none involve alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance. Gate 2 (debt): $32,608M total debt is about 19.49% of its ~$167.31B market cap, below the ~33% ceiling. Gate 3 (non-compliant income): interest income of $308M is about 0.69% of FY2025 revenue ($44,328M), below the 5% ceiling. Result: PASS. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

What is Abbott's interest-bearing debt ratio?

Per Abbott's Q2 2026 Form 10-Q (period ended June 30, 2026; SEC CIK 1800; cover: 1,730,383,296 shares outstanding), total debt was $32,608M — current portion of long-term debt $3,005M + long-term debt $29,603M. Against a market cap of about $167.31B (1,730,383,296 shares × $96.69, October 1, 2026, per Finnhub), debt ÷ market cap is about 19.49% — below the ~33% ceiling. Cash and cash equivalents of $5,104M is about 3.05% of market cap. Note: debt roughly tripled in H1 2026 ($12,929M at Dec 31, 2025 → $32,608M), alongside jumps in goodwill and intangible assets. Facts only.

What is Abbott's non-compliant income ratio?

Abbott's FY2025 Form 10-K (filed via SEC EDGAR, accession abt-20251231; CIK 1800) reports interest (income) of $308M against FY2025 net sales of $44,328M — about 0.69% of revenue, below the 5% non-compliant income ceiling. Line used: the Consolidated Statement of Earnings 'Interest (income)' line. Facts only.

Do Zoya, Musaffa, or ShariaPortfolio cover Abbott?

Zoya covers Abbott at zoya.finance/stocks/abt, but its public page renders contradictory auto-generated template text (simultaneously calling ABT 'Shariah-compliant and therefore considered halal' and 'Shariah-compliant and therefore not considered halal'), so no clean Zoya rating is retrievable without the app — honestly reported as inconclusive. (Zoya's page text also cites interest income of $230M vs the 10-K's $308M — figures differ.) Musaffa: no ABT page surfaced in search. ShariaPortfolio: no ABT entry found. All honestly reported as absent/inconclusive, not invented. This page applies the screen directly from Abbott's own SEC filings.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).